STOCK TITAN

CORCEPT THERAPEUTICS (CORT) SEC Filings, Jun-Jul 2026

CORT NASDAQ

Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.

The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.

Rhea-AI Summary

Corcept Therapeutics (CORT) affiliate Atabak Mokari filed a notice to sell 40,000 shares of common stock through Stifel Nicolaus & Company on or about July 30, 2026 on Nasdaq. The shares relate to stock option exercises dated February 13, 2023 under equity compensation.

The filing also lists prior sales over the past three months: 40,000 shares on June 1, 2026 for $2,800,004.00, 40,000 shares on June 15, 2026 for $3,245,900.00, and 40,000 shares on July 15, 2026 for $3,508,276.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.29%
Tags
quarterly report
-
Rhea-AI Summary

Corcept Therapeutics reported strong second-quarter 2026 results, with product revenue of $256.1 million, a 32 percent increase over the same period in 2025. Korlym and its authorized generic contributed $208.6 million and newly launched Lifyorli generated $47.6 million in its first quarter of sales. Net income was $43.0 million, or $0.36 per diluted share, up from $35.1 million, or $0.29 per share, a year earlier.

Operating expenses rose to $214.8 million, driven mainly by higher selling, general and administrative spending to support Lifyorli’s launch and expansion of the Cushing’s syndrome business. Cash and investments were $544.6 million at June 30, 2026.

Management increased 2026 revenue guidance to $1.1–$1.2 billion and highlighted rapid uptake of Lifyorli in platinum-resistant ovarian cancer after its March 2026 FDA approval. The company also emphasized its late-stage pipeline, including a resubmitted NDA for relacorilant in Cushing’s syndrome with a December 17, 2026 PDUFA date, an expected EMA decision on relacorilant in ovarian cancer this year, a Phase 2b MASH study reading out by year-end, and plans for a Phase 3 ALS trial of dazucorilant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.29%
Tags
current report
Rhea-AI Summary

Corcept Therapeutics director James N. Wilson reported indirect sales of 10000 shares of common stock on July 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust at weighted-average prices between $86.7777 and $89.4881 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.

After these sales, that trust held 1093464.0000 shares of common stock, while separate 2025 Grantor Retained Annuity Trusts for James and Pamela Wilson each held 200000.0000 shares indirectly; Wilson has voting power over the trust shares and disclaims beneficial ownership except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Chief Financial Officer Atabak Mokari reported option exercises and share sales in the company’s common stock. On July 15, 2026, he exercised stock options for a total of 40,000 shares at exercise prices of $23.0600 and $19.2600 per share, then sold 40,000 shares in open-market transactions at weighted average prices between $86.7760 and $89.4282 per share, with actual sale prices ranging from $86.20 to $89.43. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, and the options exercised were fully exercisable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics Chief Business Officer Gary Charles Robb reported a Form 4 showing a bona fide gift of 600 shares of Corcept Therapeutics common stock on May 27, 2026. The gift carried no sale price. After this transfer, he directly holds 25,081 shares of common stock. He also indirectly holds shares through a revocable trust with 49,716 shares and through two custodial accounts for children, each with 12,571 shares. Footnotes note additional unvested restricted stock awards scheduled to vest on the one-year anniversaries of their respective grant dates, subject to service conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics Chief Development Officer William Guyer reported a combination of option exercises and stock sales in Corcept Therapeutics common stock. He exercised stock options covering 20,000 shares at an exercise price of $21.65 per share, then sold a total of 20,000 shares in open-market transactions at weighted average prices of $93.11 and $93.54, all under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he holds 4,937 common shares directly, plus 130,000 stock options and unvested restricted stock awards that vest on their one-year anniversaries if conditions are met.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
insider
-
Rhea-AI Summary

William Guyer filed a Form 144 to sell 20,000 shares of common stock via a stock option exercise on 07/07/2026. The notice lists the sale method as Cash through Stifel Nicolaus & Company, Inc. The filing also discloses three sales in the prior three months: 20,000 shares on 04/07/2026 for $819,453, 20,000 shares on 05/05/2026 for $1,036,522, and 20,000 shares on 06/02/2026 for $1,411,993.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
other
-
Rhea-AI Summary

Corcept Therapeutics executive Sean Maduck reported option exercises and stock sales. He exercised stock options to acquire 25,000 shares of Common Stock at a strike price of $8.27 per share and sold 25,000 shares in multiple open‑market transactions at weighted average prices around $87–$89 per share under a Rule 10b5-1 trading plan adopted on December 8, 2025.

Following these transactions, he held 9,755 Common shares directly and 116,986 stock options directly, and also reported indirect holdings through trusts and LLCs, some of which he serves as trustee, co‑trustee, member, manager, or president. The filing also notes several unvested restricted stock awards that vest one year after their respective 2025–2026 grant dates if conditions are met.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, sold 10,000 shares of Common Stock on June 16, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026. The shares were sold at weighted average prices of $83.5708 and $82.6948 per share, with actual prices ranging from $82.13 to $83.935 per share. Following these sales, the trust continues to hold more than 1.09 million shares according to the filing, while two separate 2025 Grantor Retained Annuity Trusts each report indirect holdings of 200,000 shares. Wilson disclaims beneficial ownership of the trust shares except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
insider

FAQ

How many CORCEPT THERAPEUTICS (CORT) SEC filings are available on StockTitan?

StockTitan tracks 201 SEC filings for CORCEPT THERAPEUTICS (CORT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CORCEPT THERAPEUTICS (CORT)?

The most recent SEC filing for CORCEPT THERAPEUTICS (CORT) was filed on November 13, 2026.